Growth hormone treatment reduces peripheral thyroid hormone action in girls with Turner Syndrome

SUSPERREGUY S; MIRAS MB; MONTESINOS MM; MASCANFRONI ID; MUÑOZ L; SOBRERO G; SILVANO L; MASINI-REPISO AM; TARGOVNIK HM; PELLIZAS CG

Society for Endocrinology

Año: 2007 vol. 67 p. 629 - 629

b j e c t i v e Turner syndrome (TS) is an indication for GH therapy in spite of the modest growth response. Somatic growth depends not only on GH insulin-like growth factor I (IGF-I) axis but also on thyroid hormone (TH) status. We have previously reported that supraphysiological IGF-I levels diminished TH actions in rat tissues by reducing the nuclear TH receptor (TR). GH treatment to TS patients induces high IGF-I levels and therefore a reduction of TH action in tissues may be expected. We aimed at evaluating the effect of GH therapy in TS girls on peripheral TH action. De s i g n a n d p a t i e n t s We set up a reverse transcription-polymerase chain reaction (RT-PCR) for TR mRNA estimation in peripheral blood mononuclear cells (PBMC) and compared TR mRNA levels from 10 normal, 10 TS and 10 TS girls under GH therapy (0·33 mg/kg/week for 0·5–2 years). M e a s u r eme n t s After RNA extraction from PBMC, TR and β-actin mRNAs were coamplified by RT-P